Sevabertinib

Brand names: Hyrnuo · Active ingredient: Sevabertinib

In short: HYRNUO is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test . This indication is approved under acce

Forms & strengthsTablets: red brown film-coated, round, biconvex tablets debossed with "SE" on one side and "10" on the other side containing 10 mg of sevabertinib.
LabelBayer HealthCare Pharmaceuticals Inc.
Label updatedSep 23, 2026

What is Sevabertinib used for?

HYRNUO is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test .

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Sevabertinib dosage

Select patients for treatment of locally advanced or metastatic non-squamous NSCLC based on the presence of HER2 (ERBB2) TKD activating mutations in tumor specimens .

Information on FDA-authorized tests is available at http://www.fda.gov/CompanionDiagnostics.

The recommended dosage of HYRNUO is 20 mg orally twice daily with food, until disease progression or unacceptable toxicity . Swallow tablets whole. Do not cut, crush, or chew tablets.

Missed Dose

If a dose is missed, take the missed dose as soon as you remember prior to the next scheduled dose. Do not take 2 doses at the same time to make up for the missed dose.

Vomited Dose

If a dose is vomited, do not take an additional dose. Resume dosing at the next scheduled time.

The recommended dosage reductions for adverse reactions are provided in Table 1.

Dose Reduction | Dosage Modification

First | 10 mg twice daily

Second | 10 mg once daily

Permanently discontinue HYRNUO in patients who are unable to tolerate 10 mg once daily.

The recommended dosage modifications for adverse reactions are provided in Table 2.

Adverse Reaction | SeverityGrades based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. | Dosage Modification

Diarrhea | Intolerable Grade 2 or Grade 3 | Interrupt HYRNUO until recovery to Grade ≤1.

Resume HYRNUO at the same dose or the next lower dose.

For recurrence, resume HYRNUO at the next lower dose.

Grade 4 | Permanently discontinue HYRNUO.

Hepatotoxicity | Grade 2, 3 or 4 ALT and/or AST without increased total bilirubin or Grade 3 total bilirubin | Interrupt HYRNUO until recovery to Grade ≤1 or baseline.

Resume HYRNUO at the next lower dose.

ALT or AST ≥ 3× ULN with total bilirubin ≥ 2× ULN or Grade 4 total bilirubin | Permanently discontinue HYRNUO.

Interstitial Lung Disease (ILD)/Pneumonitis | Any Grade | Permanently discontinue HYRNUO.

Left Ventricular Dysfunction | LVEF 40 to 50% and decrease from baseline of 10 to 19% | Interrupt HYRNUO until recovery to Grade ≤ 1 or within 10% from baseline.

Resume HYRNUO at the same dose if recovered to Grade ≤ 1 within ≤ 4 weeks.

Permanently discontinue HYRNUO if not recovered to Grade ≤ 1 within 4 weeks.

LVEF 20 to 39% or ≥ 20% decrease from baseline | Interrupt HYRNUO until recovery to ≤ Grade 1 or within 10% from baseline.

Resume HYRNUO at the next lower dose if recovered to ≤ Grade 1 within ≤ 4 weeks.

Permanently discontinue HYRNUO if not recovered to ≤ Grade 1 within 4 weeks.

Symptomatic Congestive Heart Failure | Permanently discontinue HYRNUO.

Ocular toxicity | Grade 2 | Interrupt HYRNUO until recovery to Grade ≤1.

Resume HYRNUO at the next lower dose.

Grade 3 or Grade 4 | Permanently discontinue HYRNUO. …

How to take Sevabertinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Diarrhea

Inform patients that HYRNUO can cause severe diarrhea. At the first sign of diarrhea or increased bowel movement frequency, instruct patients to start an antidiarrheal treatment (e.g., loperamide), to increase their fluid and electrolyte intake, and to immediately contact their healthcare provider .

Hepatotoxicity

Inform patients that HYRNUO can cause severe hepatotoxicity characterized by elevations of liver function tests. Inform patients that they will need to undergo lab tests to monitor hepatic function. Advise patients to immediately contact their healthcare provider for signs and symptoms of hepatotoxicity .

Interstitial Lung Disease (ILD)/Pneumonitis

Inform patients that HYRNUO can cause ILD/pneumonitis. Advise patients to immediately contact their healthcare provider for new or worsening respiratory symptoms .

Left Ventricular Dysfunction

Inform patients that HYRNUO can cause severe left ventricular dysfunction. Advise patients to immediately contact their healthcare provider for new or worsening cardiovascular symptoms . …

Warnings & precautions

Do not take this medicine if: None.

HYRNUO can cause severe diarrhea that can lead to dehydration and electrolyte imbalances. In the pooled safety population , diarrhea was reported in 89% of patients who received HYRNUO including 16% Grade 3. The median time to first onset of any grade diarrhea was four days. Dosage interruptions occurred in 15% of patients, and dose reductions occurred in 14% of patients.

At the first sign of diarrhea or increased bowel movement frequency, instruct patients to start an antidiarrheal treatment (e.g., loperamide [refer to full Prescribing Information]), and to increase their fluid and electrolyte intake. Interrupt, reduce the dose, or permanently discontinue HYRNUO based on severity .

HYRNUO can cause severe hepatotoxicity characterized by elevations of liver function tests. In the pooled safety population , based on adverse reaction data, hepatotoxicity occurred in 29% of patients treated with HYRNUO, including 3.1% Grade 3 and 0.3% Grade 4. Based on laboratory data, 41% of patients treated with HYRNUO experienced increased alanine aminotransferase (ALT), including 2.5% Grade 3 and 0.4% Grade 4. Increased aspartate aminotransferase (AST) occurred in 44% of patients treated with HYRNUO, including 2.5% Grade 3. Increased bilirubin occurred in 15% of patients treated with HYRNUO. The median time to first onset of AST or ALT elevation was 1.4 (range 0.2 to 24.1) months. HYRNUO was interrupted for an adverse reaction of hepatotoxicity in 4.2% of patients, the dose was reduced in 4.9% and permanently discontinued in 0.3%.

Monitor liver function tests including ALT, AST, and total bilirubin at baseline prior to the first administration of HYRNUO, every 2 weeks for the first month, and then monthly thereafter as clinically indicated, with more frequent testing in patients who develop transaminase elevations. …

Sevabertinib side effects

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

Diarrhea

Hepatotoxicity

Interstitial Lung Disease (ILD)/Pneumonitis

Left Ventricular Dysfunction

Ocular Toxicity

Pancreatic Enzyme Elevation

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population in the WARNINGS AND PRECAUTIONS reflects exposure to HYRNUO at 20 mg orally twice daily in 287 patients with locally advanced or metastatic NSCLC harboring HER2 activating and/or other mutations from the SOHO-01 study . Among 287 patients who received HYRNUO, 61% were exposed for greater than 6 months and 37% were exposed for greater than 1 year.

In this pooled safety population, the most common (>20%) adverse reactions were diarrhea, rash, paronychia, nausea, vomiting, and stomatitis. The most common (≥2%) Grade 3 or 4 laboratory abnormalities were decreased potassium, increased lipase, decreased phosphate, decreased lymphocyte count, decreased sodium, increased amylase, decreased hemoglobin, increased ALT, increased AST, and decreased calcium. …

Drug interactions

Table 6 describes drug interactions where concomitant use of another drug affects HYRNUO.

Strong and Moderate CYP3A Inhibitors

Prevention or management | Strong CYP3A Inhibitors:

Avoid concomitant use of HYRNUO with strong CYP3A inhibitors.

If concomitant use cannot be avoided, reduce HYRNUO dosage .

Moderate CYP3A Inhibitors:

Monitor patients for increased HYRNUO-associated adverse reactions .

Mechanism and Clinical Effect | Sevabertinib is a CYP3A substrate.

Concomitant use with a strong or moderate CYP3A inhibitor may increase sevabertinib plasma concentrations , which may increase the risk of HYRNUO-associated adverse reactions.

Strong and Moderate CYP3A Inducers

Prevention or management | Avoid concomitant use of HYRNUO with strong or moderate CYP3A inducers.

Mechanism and Clinical Effect | Sevabertinib is a CYP3A substrate.

Concomitant use with a strong or moderate CYP3A inducer may decrease sevabertinib plasma concentrations , which may decrease the effectiveness of HYRNUO.

Table 7 describes drug interactions where concomitant use of HYRNUO affects another drug. …

About this medicine

HYRNUO tablets contain sevabertinib, a kinase inhibitor. The chemical name of the drug substance is 3-(3-chloro-2-methoxyanilino)-2-{3-[(2S)-1,4-dioxan-2-ylmethoxy]pyridin-4-yl}-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one hydrate. The molecular formula is C24H25ClN4O5 (anhydrate) and the molecular weight is 484.93 g/mol (anhydrate).

The structural formula is shown below:

Sevabertinib is present as a non-stoichiometric hydrate as a white to off-white to yellow to pinkish powder. It is slightly soluble in aqueous solution at pH 2, and practically insoluble in aqueous solutions at pH 4.5 and above.

The strength of HYRNUO is based on the anhydrate form. Each HYRNUO tablet for oral use contains 10 mg of sevabertinib. The inactive ingredients are: cellulose microcrystalline, crospovidone, lactose monohydrate, and magnesium stearate. The tablet film coating contains ferric oxide red, hypromellose 5 cP, and macrogol 3350.

How it works: Sevabertinib is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d7a11334-6e7a-445b-9a16-bdcd9acbe61f. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate